A Phase 3 interventional study of Levetiracetam in Epilepsy, sponsored by UCB Pharma. Completed at 35 sites in 6 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-05-18.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 23rd largest by enrollment, is one of 5 that started in 2006, is one of 28 in phase 3, and was the 14th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 53rd largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2006, is one of 74 in phase 3, and was the 20th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
For ethical reasons to give opportunity for adult subjects (≥16 or 18 years) suffering from newly diagnosed epilepsy who completed the therapeutic confirmatory, open-label trial N01175 (NCT00175903) conducted with levetiracetam in monotherapy and who benefited from the treatment, to receive treatment with levetiracetam until the monotherapy indication for levetiracetam is granted in Europe.
To continue to assess safety of levetiracetam as per adverse event reporting and observation of weight changes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other inclusion criteria may apply
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Levetiracetam
500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase
Summarization for occurrence of adverse events like number of subjects with any adverse events or drug related adverse events is provided (see categories).
Time frame: during open-label therapy phase of 18 months
Change From Baseline in Body Weight to Withdrawal or End of Study After 18 Months
Time frame: Start of open-label therapy (Baseline) to withdrawal or end of study after 18 months
Participants Flow describes all subjects treated at least once during open-label monotherapy with Levetiracetam.
| Milestone | Levetiracetam Open- Label Treatment |
|---|---|
| Started | 130 |
| Completed | 115 |
| Not completed | 15 |
Summarization for occurrence of adverse events like number of subjects with any adverse events or drug related adverse events is provided (see categories).
| participants | Levetiracetam Open- Label Treatment |
|---|---|
| Subjects with at least one AE | 40 |
| Subjects with AEs leading to dose change | 8 |
| Subjects with AEs leading to trial discontinuation | 1 |
| Subjects with drug-related AEs | 16 |
| Subjects with AEs of severe intensity | 4 |
| Subjects with serious AEs | 6 |
| Subjects with study drug-related serious AEs | 0 |
| Number of deaths | 0 |
| kg | Levetiracetam Open- Label Treatment |
|---|---|
| Change From Baseline in Body Weight to Withdrawal or End of Study After 18 Months | 0.71 ± 3.16 |
Collected over Open-label treatment over 18 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam Open- Label Treatment | — | 6/130 (4.6%) | 10/130 (7.7%) |
| Event | Levetiracetam Open- Label Treatment |
|---|---|
| Acute coronary syndromeCardiac disorders | 1/130 |
| Hepatic cirrhosisHepatobiliary disorders | 1/130 |
| Skin lacerationInjury, poisoning and procedural complications | 1/130 |
| Grand mal convulsionNervous system disorders | 1/130 |
| AlcoholismPsychiatric disorders | 1/130 |
| TonsillitisInfections and infestations | 1/130 |
| Foot fractureInjury, poisoning and procedural complications | 1/130 |
| Event | Levetiracetam Open- Label Treatment |
|---|---|
| Weight increasedInvestigations | 7/130 |
| Weight decreasedInvestigations | 3/130 |
| Age, Continuous(years) | Levetiracetam Open- Label Treatment |
|---|---|
| Mean | 40.68 ± 18.35 |
| Sex: Female, Male(Participants) | Levetiracetam Open- Label Treatment |
|---|---|
| Female | 58 |
| Male | 72 |
| Region of Enrollment(participants) | Levetiracetam Open- Label Treatment |
|---|---|
| France | 18 |
| Finland | 9 |
| Poland | 32 |
| Belgium | 25 |
| Bulgaria | 31 |
| Switzerland | 15 |
The record gives a start of Jun 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam